



## Patient Safety Component—Annual Facility Survey for LTAC

Page 2 of 17

### Facility Microbiology Laboratory Practices (completed with input from Microbiology Laboratory Lead)

\*1. Does your facility have its own on-site laboratory that performs bacterial antimicrobial susceptibility testing?  Yes  No

1a. If No, where is your facility's antimicrobial susceptibility testing performed? (check one)

- Affiliated medical center     
  Commercial referral laboratory     
  Other local/regional, non-affiliated reference laboratory

\*2. For the following organisms, please indicate which methods are used for:

- (1) Primary susceptibility testing and  
(2) Secondary, supplemental, or confirmatory testing (if performed).

If your laboratory does not perform susceptibility testing, please indicate the methods used at the outside laboratory.

**Please use the testing codes listed below the table.**

Pathogen	(1) Primary	(2) Secondary	Comments
<i>Staphylococcus aureus</i>	_____	_____	_____
Enterobacteriales	_____	_____	_____
1 = Kirby-Bauer disk diffusion	4 = Sensititre	7 = Agar dilution method	
2 = Vitek (Legacy)	5.1 = MicroScan WalkAway	10 = E test	
2.1 = Vitek 2	5.2 = MicroScan autoSCAN	12 = Vancomycin agar screen (BHI + vancomycin)	
3.1 = BD Phoenix	6 = Other broth microdilution method	13 = Other (describe in Comments section)	

\*3. Does either the primary or secondary/supplemental antimicrobial susceptibility testing of *Pseudomonas* spp., include ceftolozane-tazobactam?  Yes  No  N/A – no AST performed for *Pseudomonas*

\*4. Has the laboratory implemented the revised cephalosporin and monobactam breakpoints for Enterobacteriaceae recommended by CLSI as of 2010? (As of 2020, this includes organisms in the order Enterobacteriales.)  Yes  No

\*5. Has the laboratory implemented the revised carbapenem breakpoints for Enterobacteriaceae recommended by CLSI as of 2010? (As of 2020, this includes organisms in the order Enterobacteriales.)  Yes  No

\*6. Does the laboratory perform a test for presence of carbapenemase? (this does not include automated testing instrument expert rules)  Yes  No

6a. If Yes, please indicate what is done if carbapenemase production is detected: (check one)

- Change susceptible carbapenem results to resistant  
 Report carbapenem MIC results without an interpretation  
 No changes are made in the interpretation of carbapenems, the test is used for epidemiological or infection control practices

*Continued >>*

## Patient Safety Component—Annual Facility Survey for LTAC

Page 3 of 17

### Facility Microbiology Laboratory Practices (continued)

6b. If Yes, which test is routinely performed to detect carbapenemase: (check all that apply)

- |                                              |                                                            |                                   |
|----------------------------------------------|------------------------------------------------------------|-----------------------------------|
| <input type="checkbox"/> PCR                 | <input type="checkbox"/> MBL Screen                        | <input type="checkbox"/> mCIM/CIM |
| <input type="checkbox"/> Modified Hodge Test | <input type="checkbox"/> Carba NP                          |                                   |
| <input type="checkbox"/> Rapid CARB Blue     | <input type="checkbox"/> Cepheid, BioFire array, Verigene® |                                   |
| <input type="checkbox"/> E test              | <input type="checkbox"/> Other (specify): _____            |                                   |

6c. If Yes, which of the following are routinely tested for the presence of carbapenemases: (check all that apply)

- Enterobacterales spp.     *Pseudomonas aeruginosa*     *Acinetobacter baumannii*

\*7. Does your facility perform extended-spectrum beta-lactamase (ESBL) testing for *E. coli* and/or *Klebsiella* spp. either routinely or using a testing algorithm?

Yes     No

7a. If Yes, please indicate what is done if ESBL is detected: (check one)

- Change susceptible Cefotaxime/Ceftriaxone/Cefepime results to resistant  
 No changes are made in the interpretation of cephalosporins with a note of ESBL  
 Suppress cephalosporin susceptibility results

\*8. Where is yeast identification performed for specimens collected at your facility? (check one)

- On-site laboratory  
 Affiliated medical center  
 Commercial referral laboratory  
 Other local/regional, non-affiliated reference laboratory  
 Yeast identification not available (i.e., yeast identification is not performed onsite or at any affiliate/commercial/other laboratory) [If checked, skip questions 9-13]

### Answer questions 9–13 for the laboratory that performs yeast identification for your facility:

\*9. Which of the following methods are used for yeast identification? (check all that apply)

- |                                                                |                                                                                                     |
|----------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> MALDI-TOF MS System (Vitek MS)        | <input type="checkbox"/> MicroScan                                                                  |
| <input type="checkbox"/> MALDI-TOF MS System (Bruker Biotyper) | <input type="checkbox"/> Non-automated Manual Kit (e.g., API 20C, RapID, Germ Tube, PNA-FISH, etc.) |
| <input type="checkbox"/> Vitek-2                               | <input type="checkbox"/> DNA sequencing                                                             |
| <input type="checkbox"/> BD Phoenix                            | <input type="checkbox"/> Other (specify) _____                                                      |

\*10. Does the laboratory routinely use Chromagar for the identification or differentiation of *Candida* isolates?

- Yes     No     Unknown

Continued >>

## Patient Safety Component—Annual Facility Survey for LTAC

Page 4 of 17

### Facility Microbiology Laboratory Practices (continued)

\*11. *Candida* isolated from which of the following body sites are usually fully identified to the species level? (check all that apply)

- |                                                                       |                                                                         |
|-----------------------------------------------------------------------|-------------------------------------------------------------------------|
| <input type="checkbox"/> Blood                                        | <input type="checkbox"/> Respiratory                                    |
| <input type="checkbox"/> Other normally sterile body site (e.g., CSF) | <input type="checkbox"/> Other (specify): _____                         |
| <input type="checkbox"/> Urine                                        | <input type="checkbox"/> None are fully identified to the species level |

\*12. Does the laboratory employ any culture-independent diagnostic tests (CIDT) to identify *Candida* from blood specimens?

- Yes                       No                       Unknown

12a. If yes, which culture-independent diagnostic tests (CIDT) are used to identify *Candida* from blood specimens? (check all that apply)

- T2Candida Panel  
 BioFire  
 Other, specify: \_\_\_\_\_  
 Unknown

\*13. Are any culture-independent diagnostic tests (CIDT) used to specifically identify *Candida auris* from clinical specimens?

- Yes                       No                       Unknown

13a. If yes, which culture-independent diagnostic tests (CIDT) are used to identify *Candida auris* from clinical specimens? (check all that apply)

- T2Cauris Panel  
 PCR  
 Other, specify: \_\_\_\_\_  
 Unknown

\*14. Where is antifungal susceptibility testing (AFST) performed for specimens collected at your facility? (check one)

- |                                                         |                                                                                                                                                                      |
|---------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> On-site laboratory             | <input type="checkbox"/> Other local/regional, non-affiliated reference laboratory                                                                                   |
| <input type="checkbox"/> Affiliated medical center      | <input type="checkbox"/> AFST not available (i.e., AFST is not performed onsite or at any affiliate/commercial/other laboratory) [if selected, skip questions 15-17] |
| <input type="checkbox"/> Commercial referral laboratory |                                                                                                                                                                      |

**Answer questions 15–17 for the laboratory that performs AFST for your facility:**

\*15. What method is used for antifungal susceptibility testing (AFST)? (check all that apply)

- |                                              |                                                              |                                  |                                       |
|----------------------------------------------|--------------------------------------------------------------|----------------------------------|---------------------------------------|
| <input type="checkbox"/> Broth microdilution | <input type="checkbox"/> YeastOne colorimetric microdilution | <input type="checkbox"/> E test  | <input type="checkbox"/> Vitek 2 card |
| <input type="checkbox"/> Disk diffusion      | <input type="checkbox"/> Other (specify): _____              | <input type="checkbox"/> Unknown |                                       |

Continued >>

## Patient Safety Component—Annual Facility Survey for LTAC

Page 5 of 17

### Facility Microbiology Laboratory Practices (continued)

15a. If Vitek is used for AFST, which *Candida* species do you test with it? (check all that apply)

- C. albicans*                       *C. parapsilosis*  
 *C. glabrata*                       Other *Candida* spp.

\*16. AFST is performed for which of the following antifungal drugs? (check all that apply)

- Fluconazole                       Micafungin                       Flucytosine  
 Voriconazole                       Anidulafungin                       Other, specify: \_\_\_\_\_  
 Itraconazole                       Caspofungin                       Unknown  
 Posaconazole                       Amphotericin B

\*17. AFST is performed on fungal isolates in which of the following situations? (check only one box per row)

	Performed automatically/ reflexively	Performed with a clinician's order	Not performed	Unknown
Blood	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other normally sterile body site (e.g., CSF)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Urine	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Respiratory	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Other (specify): _____	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

\*18. What is the primary testing method for *C. difficile* used most often by your facility's laboratory or the outside laboratory where your facility's testing is performed? (check one)

- Enzyme immunoassay (EIA) for toxin  
 Cell cytotoxicity neutralization assay  
 Nucleic acid amplification test (NAAT) (e.g., PCR, LAMP)  
 NAAT plus EIA, if NAAT positive (2-step algorithm)  
 Glutamate dehydrogenase (GDH) antigen plus EIA for toxin (2-step algorithm)  
 GDH plus NAAT (2-step algorithm)  
 GDH plus EIA for toxin, followed by NAAT for discrepant results  
 Toxigenic culture (*C. difficile* culture followed by detection of toxins)  
 Other (specify): \_\_\_\_\_

*Continued >>*

## Patient Safety Component—Annual Facility Survey for LTAC

Page 6 of 17

### Facility Microbiology Laboratory Practices (continued)

\*19. Please indicate the primary and definitive method used to identify microbes from blood cultures collected in your facility. (check one)

- MALDI-TOF MS System (Vitek MS)
- MALDI-TOF MS System (Bruker Biotyper)
- Automated Instrument (e.g., Vitek, MicroScan, Phoenix, OmniLog, Sherlock, etc.)
- Non-automated Manual Kit (e.g., API, Crystal, RapID, etc.)
- Rapid Identification (e.g., Verigene, BioFire FilmArray, PNA-FISH, Gene Xpert, etc.)
- 16S rRNA Sequencing
- Other (specify): \_\_\_\_\_
- None

\*20. Please indicate any additional secondary methods used for microbe identification from blood cultures collected in your facility (e.g., a rapid method that is confirmed with the primary method, a secondary method if the primary method fails to give an identification, or a method that is used in conjunction with the primary method). (check all that apply)

- MALDI-TOF MS System (Vitek MS)
- MALDI-TOF MS System (Bruker Biotyper)
- Automated Instrument (e.g., Vitek, MicroScan, Phoenix, OmniLog, Sherlock, etc.)
- Non-automated Manual Kit (e.g., API, Crystal, RapID, etc.)
- Rapid Identification (e.g., Verigene, BioFire FilmArray, PNA-FISH, Gene Xpert, etc.)
- 16S rRNA Sequencing
- Other (specify): \_\_\_\_\_
- None

### Infection Control Practices (completed with input from Hospital Epidemiologist and/or Quality Improvement Coordinator)

\*21. Number or fraction of infection preventionists (IPs) in facility:

- a. Total hours per week performing surveillance: \_\_\_\_\_
- b. Total hours per week for infection control activities other than surveillance: \_\_\_\_\_

\*22. Number or fraction of full-time employees (FTEs) for a designated hospital epidemiologist (or equivalent role) affiliated with your facility: \_\_\_\_\_

\*23. Is it a policy in your facility that patients infected or colonized with MRSA are routinely placed in contact precautions while these patients are in your facility? (check one)

- Yes                     
  No                             
  Not applicable: my facility never admits these patients

*Continued >>*

## Patient Safety Component—Annual Facility Survey for LTAC

Page 7 of 17

### Infection Control Practices (continued)

23a. If Yes, please check the type of patients that are routinely placed in contact precautions while in your facility (check one):

- All infected and all colonized patients
- Only all infected patients
- Only infected or colonized patients with certain characteristics (check all that apply)
  - Patients admitted to high risk settings
  - Patients at high risk for transmission

\*24. Is it a policy in your facility that patients infected or colonized with VRE are routinely placed in contact precautions while these patients are in your facility? (check one)

- Yes
- No
- Not applicable: my facility never admits these patients

24a. If Yes, please check the type of patients that are routinely placed in contact precautions while in your facility (check one):

- All infected and all colonized patients
- Only all infected patients
- Only infected or colonized patients with certain characteristics (check all that apply)
  - Patients admitted to high risk settings
  - Patients at high risk for transmission

\*25. Is it a policy in your facility that patients infected or colonized with CRE (regardless of confirmatory testing for carbapenemase production) are routinely placed in contact precautions while these patients are in your facility? (check one)

- Yes
- No
- Not applicable: my facility never admits these patients

25a. If Yes, please check the type of patients that are routinely placed in contact precautions while in your facility (check one):

- All infected and all colonized patients
- Only all infected patients
- Only infected or colonized patients with certain characteristics (check all that apply)
  - Patients admitted to high risk settings
  - Patients at high risk for transmission

*Continued >>*

## Patient Safety Component—Annual Facility Survey for LTAC

Page 8 of 17

### Infection Control Practices (continued)

\*26. Is it a policy in your facility that patients infected or colonized with suspected or confirmed ESBL-producing or extended spectrum cephalosporin resistant Enterobacterales are routinely placed in contact precautions while these patients are in your facility? (check one)

- Yes
- No
- Not applicable: my facility never admits these patients

26a. If Yes, please check the type of patients that are routinely placed in contact precautions while in your facility (check one):

- All infected and all colonized patients
- Only all infected patients
- Only infected or colonized patients with certain characteristics (check all that apply)
  - Patients admitted to high-risk settings
  - Patients at high risk for transmission

\*27. Does the facility routinely perform screening testing (culture or non-culture) for CRE? *This includes screening for patients at your facility performed by public health laboratories and commercial laboratories*

Yes  No

27a. If Yes, in which situations does the facility routinely perform screening testing for CRE? (check all that apply)

- Surveillance testing at admission for all patients
- Surveillance testing of epidemiologically-linked patients of newly identified CRE patients (e.g., roommates)
- Surveillance testing at admission of high-risk patients (check all that apply)
  - Patients admitted from long-term acute care (LTAC) or long-term care facility (LTCF)
  - Patients with recent (e.g., within 6 months) overnight hospital stay outside the United States
  - Patients admitted to high-risk settings (e.g., ICU)
  - Other high-risk patients (specify): \_\_\_\_\_
- Other (specify): \_\_\_\_\_

\*28. Does the facility routinely perform screening testing (culture or non-culture) for MRSA for any patients admitted?

Yes  No

*Continued >>*



## Patient Safety Component—Annual Facility Survey for LTAC

Page 9 of 17

### Infection Control Practices (continued)

28a. If yes, in which situations does the facility routinely perform screening testing for MRSA? (check all that apply)

- Surveillance testing at admission for all patients
- Surveillance testing at admission of high-risk patients (e.g., admitted from long-term acute care [LTAC] or long-term care facility [LTCF])
- Surveillance testing at admission of patients admitted to high-risk settings (e.g., ICU)
- Surveillance testing of pre-operative patients to prevent surgical site infections
- Other (specify): \_\_\_\_\_

\*29. Does your facility have a policy to routinely use chlorhexidine bathing for any adult patients?  Yes  No

\*30. Does the facility have a policy to routinely use a combination of topical chlorhexidine AND an intranasal antistaphylococcal agent (mupirocin, iodophor, or an alcohol based intranasal agent) for any adult patients to prevent healthcare-associated infections or reduce transmission of resistant pathogens?  Yes  No

### Antibiotic Stewardship Practices

(completed with input from Physician and Pharmacist Stewardship Leaders)

\*31. Did the antibiotic stewardship leader(s) participate in responding to these questions? (Check one.)

- Yes, pharmacist lead
- Yes, physician lead
- Yes, both pharmacist and physician leads
- Yes, other lead
- No

\*32. Facility leadership has demonstrated commitment to antibiotic stewardship efforts by: (Check all that apply.)

- Providing stewardship program leader(s) dedicated time to manage the program and conduct daily stewardship interventions.
- Allocating resources (e.g., IT support, training for stewardship team) to support antibiotic stewardship efforts.
- Having a senior executive that serves as a point of contact or “champion” to help ensure the program has resources and support to accomplish its mission.
- Presenting information on stewardship activities and outcomes to facility leadership and/or board at least annually.
- Ensuring the stewardship program has an opportunity to discuss resource needs with facility leadership and/or board at least annually.
- Communicating to staff about stewardship activities, via email, newsletters, events, or other avenues.

*Continued >>*

## Patient Safety Component—Annual Facility Survey for LTAC

Page 10 of 17

### Antibiotic Stewardship Practices (continued)

- Providing opportunities for hospital staff training and development on antibiotic stewardship.
- Providing a formal statement of support for antibiotic stewardship (e.g., a written policy or statement approved by the board).
- Ensuring that staff from key support departments and groups (e.g., IT and hospital medicine) are contributing to stewardship activities.
- None of the above

\*33. Our facility has a leader or co-leaders responsible for antibiotic stewardship program management and outcomes.  Yes  No

33a. If Yes, what is the position of this leader? (Check one.)

- Physician
- Pharmacist
- Co-led by both Pharmacist and Physician
- Other (e.g., RN, PA, NP, etc.; specify): \_\_\_\_\_

33b. If Physician or Co-led is selected, which of the following describes your antibiotic stewardship **physician** leader? (Check all that apply.)

- Has antibiotic stewardship responsibilities in their contract or job description
- Is physically on-site in your facility (either part-time or full-time)
- Completed an ID fellowship
- Completed a certificate program on antibiotic stewardship
- Completed training courses (e.g., conferences or online modules) on antibiotic stewardship
- None of the above

33c. If 'Has antibiotic stewardship responsibilities in their contract or job description' is selected (for physician (co) leader): What percent time for antibiotic stewardship activities is specified in the **physician** (co) leader's **contract or job description**? (Check one.)

- 1-25%
- 51-75%
- Not specified
- 26-50%
- 76-100%

33d. If Physician or Co-led is selected: **In an average week**, what percent time does the **physician** (co) leader **spend** on antibiotic stewardship activities in your facility? (Check one.)

- 1-25%
- 76-100%
- 26-50%
- Not specified
- 51-75%

*Continued >>*

## Patient Safety Component—Annual Facility Survey for LTAC

Page 11 of 17

### Antibiotic Stewardship Practices (continued)

33e. If Pharmacist or Co-led is selected, which of the following describes your antibiotic stewardship **pharmacist** leader? (Check all that apply.)

- Has antibiotic stewardship responsibilities in their contract or job description
- Is physically on-site in your facility (either part-time or full-time)
- Completed a PGY2 ID residency and/or ID fellowship
- Completed a certificate program on antibiotic stewardship
- Completed training courses (e.g., conferences or online modules) on antibiotic stewardship
- None of the above

33f. If 'Has antibiotic stewardship responsibilities in their contract or job description' is selected (for pharmacist (co) leader): What percent time for antibiotic stewardship activities is specified in the **pharmacist** (co) leader's **contract or job description**? (Check one)

- 1-25%
- 26-50%
- 51-75%
- 76-100%
- Not specified

33g. If 'Pharmacist' or 'Co-led' is selected: **In an average week**, what percent time does the **pharmacist** (co) leader **spend** on antibiotic stewardship activities in your facility? (Check one)

- 1-25%
- 26-50%
- 51-75%
- 76-100%
- Not specified

33h. If Pharmacist or Other is selected: Does your facility have a designated physician who can serve as a point of contact and support for the non-physician leader?

- Yes  No

33i. If a pharmacist is **not** the leader or co-leader for the program, is there at least one pharmacist responsible for improving antibiotic use at your facility?

- Yes  No

\*34. Our facility has the following priority antibiotic stewardship interventions: (Check all that apply)

- Prospective audit and feedback for specific antibiotic agents

34a. If Prospective audit and feedback is selected: For which categories of antimicrobials? Please answer for the following categories of antimicrobials, *whether or not* they are on formulary. (Check all that apply)

- Cefepime, ceftazidime, or piperacillin/tazobactam
- Vancomycin (intravenous)
- Ertapenem, imipenem/cilastatin, or meropenem
- Ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, imipenem-cilastatin/relebactam, or cefiderocol

Continued >>

## Patient Safety Component—Annual Facility Survey for LTAC

Page 12 of 17

### Antibiotic Stewardship Practices (continued)

- Fluoroquinolones
- Daptomycin, linezolid, or other newer anti-MRSA agents
- Eravacycline or omadacycline
- Lefamulin
- Aminoglycosides
- Colistin or polymyxin B
- Anidulafungin, caspofungin, or micafungin
- Isavuconazole, posaconazole, or voriconazole
- Amphotericin B and/or lipid-based amphotericin B
- None of the above

34b. If Prospective audit and feedback is selected: Our antibiotic stewardship program monitors prospective audit and feedback interventions (e.g., by tracking antibiotic use, types of interventions, acceptance of recommendations).

Yes  No

- Preauthorization for specific antibiotic agents.

34c. If Preauthorization is selected: For which categories of antimicrobials? Please only answer for categories of antimicrobials that are *on formulary*. (Check all that apply)

- Cefepime, ceftazidime, or piperacillin/tazobactam
- Vancomycin (intravenous)
- Ertapenem, imipenem/cilastatin, or meropenem
- Ceftazidime/avibactam, ceftolozane/tazobactam, meropenem/vaborbactam, imipenem-cilastatin/relebactam, or cefiderocol
- Fluoroquinolones
- Daptomycin, linezolid, or other newer anti-MRSA agents
- Eravacycline or omadacycline
- Lefamulin
- Aminoglycosides
- Colistin or polymyxin B
- Anidulafungin, caspofungin, or micafungin
- Isavuconazole, posaconazole, or voriconazole
- Amphotericin B and/or lipid-based amphotericin B
- None of the above

Continued >>

## Patient Safety Component—Annual Facility Survey for LTAC

Page 13 of 17

### Antibiotic Stewardship Practices (continued)

34d. If Preauthorization is selected: Our antibiotic stewardship program monitors preauthorization interventions (e.g., by tracking which agents are requested for which conditions).

Yes  No

Facility-specific treatment recommendations, based on national guidelines and local pathogen susceptibilities, to assist with antibiotic selection for common clinical conditions (e.g., community acquired pneumonia, urinary tract infection, skin and soft tissue infection).

34e. If Facility-specific treatment recommendations is selected: Our stewardship program monitors adherence to our facility's treatment recommendations for antibiotic selection for common clinical conditions (e.g., community acquired pneumonia, urinary tract infection, skin and soft tissue infection).

Yes  No

None of the above

\*35. Our facility has a policy or formal procedure for other interventions to ensure optimal use of antibiotics: (Check all that apply.)

Early administration of effective antibiotics to optimize the treatment of sepsis

Treatment protocols for *Staphylococcus aureus* bloodstream infection

Stopping unnecessary antibiotic(s) in new cases of *Clostridioides difficile* infection (CDI)

Review of culture-proven invasive (e.g., bloodstream) infections

Review of planned outpatient parenteral antibiotic therapy (OPAT)

The treating team to review antibiotics 48-72 hours after initial order (i.e., antibiotic time-out).

Assess and clarify documented penicillin allergy

Using the shortest effective duration of antibiotics at discharge for common clinical conditions (e.g., community-acquired pneumonia, urinary tract infections, skin and soft tissue infections)

None of the above

35b. If 'Using the shortest effective duration of antibiotics at discharge for common clinical conditions' is selected: Our stewardship program monitors adherence to use of shortest effective duration of antibiotics at discharge for common clinical conditions (e.g., community-acquired pneumonia, urinary tract infections, skin and soft tissue infections), at least annually.

Yes  No

Continued >>

## Patient Safety Component—Annual Facility Survey for LTAC

Page 14 of 17

### Antibiotic Stewardship Practices (continued)

\*36. Our facility has in place the following specific 'pharmacy-based' interventions: (Check all that apply)

- Pharmacy-driven changes from intravenous to oral antibiotics without a physician's order (e.g., hospital-approved protocol)
- Alerts to providers about potentially duplicative antibiotic spectra (e.g., multiple antibiotics to treat anaerobes)
- Automatic antibiotic stop orders in specific situations (e.g., surgical prophylaxis)
- None of the above

\*37. Our stewardship program has engaged bedside nurses in actions to optimize antibiotic use.

Yes  No

37a. If Yes is selected: Our facility has in place the following specific 'nursing-based' interventions: (Check all that apply.)

- Nurses receive training on appropriate criteria for sending urine and/or respiratory cultures.
- Nurses initiate discussions with the treating team on switching from intravenous to oral antibiotics.
- Nurses initiate antibiotic time-out discussions with the treating team.
- Nurses track antibiotic duration of therapy

37b. If 'Nurses track antibiotic duration of therapy' is selected: Is that information available at the bedside (e.g., on a whiteboard in the room)?

Yes  No

\*38. Our stewardship program monitors: (Check all that apply.)

- Antibiotic resistance patterns (either facility- or region-specific), at least annually
- Clostridioides difficile* infections (or *C. difficile* LabID events), at least annually
- Antibiotic use in days of therapy (DOT) per 1000 patient days or days present, at least quarterly
- Antibiotic use in defined daily doses (DDD) per 1000 patient days, at least quarterly
- Antibiotic expenditures (i.e., purchasing costs), at least quarterly
- Antibiotic use in some other way, at least annually (specify): \_\_\_\_\_
- None of the above

\*39. Our stewardship team provides the following reports on antibiotic use to prescribers, at least annually: (Check all that apply.)

- Individual, prescriber-level reports
- Unit- or service-specific reports
- None of the above

Continued >>

## Patient Safety Component—Annual Facility Survey for LTAC

Page 15 of 17

### Antibiotic Stewardship Practices (continued)

39a. If 'Individual, prescriber-level reports' or 'Unit- or service-specific reports' is selected: Our stewardship program uses these reports to target feedback to prescribers about how they can improve their antibiotic prescribing, at least annually.

Yes       No

\*40. Our facility distributes an antibiogram to prescribers, at least annually

Yes       No

\*41. Information on antibiotic use, antibiotic resistance, and stewardship efforts is reported to hospital staff, at least annually.

Yes       No

\*42. Which of the following groups receive education on optimal prescribing, adverse reactions from antibiotics, and antibiotic resistance at least annually? (Check all that apply.)

- Prescribers
- Nursing staff
- Pharmacists
- None of the above

\*43. Are patients provided education on important side effects of prescribed antibiotics?

Yes       No

43a. If 'Yes' is selected: How is education to patients on side effects shared? (Check all that apply.)

- Discharge paperwork
- Verbally by nurse
- Verbally by pharmacist
- Verbally by physician
- None of the above

### Optional Antibiotic Stewardship Practices Questions

**Responses to the following questions are not required to complete the annual survey.**

**Please provide additional information about your facility's antibiotic stewardship activities and leadership.**

44. Antibiotic stewardship activities are integrated into quality improvement and/or patient safety initiatives.

Yes       No

45. Our facility accesses targeted remote stewardship expertise (e.g., tele-stewardship to obtain facility-specific support for our antibiotic stewardship efforts

Yes       No

*Continued >>*

## Patient Safety Component—Annual Facility Survey for LTAC

Page 16 of 17

### Optional Antibiotic Stewardship Practices (continued)

46. Our stewardship program works with the microbiology laboratory to implement the following interventions: (Check all that apply)

- Selective reporting of antimicrobial susceptibility testing results
- Placing comments in microbiology reports to improve prescribing
- None of the above

47. Which committees or leadership entities provide oversight of your facility's antibiotic stewardship efforts? (Check all that apply.)

- |                                                  |                                                                |
|--------------------------------------------------|----------------------------------------------------------------|
| <input type="checkbox"/> Pharmacy director       | <input type="checkbox"/> Executive leadership (e.g., CEO, CMO) |
| <input type="checkbox"/> Pharmacy & therapeutics | <input type="checkbox"/> Hospital board                        |
| <input type="checkbox"/> Patient safety          | <input type="checkbox"/> Other (specify): _____                |
| <input type="checkbox"/> Quality improvement     | <input type="checkbox"/> None                                  |

### Facility Water Management Program (WMP) (Completed with input from WMP team members.)

\*48. Has your facility ever conducted an environmental assessment to identify where *Legionella* and other opportunistic waterborne pathogens (e.g., *Pseudomonas*, *Acinetobacter*, *Burkholderia*, *Stenotrophomonas*, nontuberculous mycobacteria, and fungi) could grow and spread in the facility water system (e.g., piping infrastructure)? This may include a basic diagram that maps all water supply sources, treatment systems, processing steps, control measures, and end-use points.

Yes       No

48a. If Yes, when was the most recent assessment conducted? (Check one)

- |                                                                         |                                                                                 |                                                                |
|-------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------|
| <input type="checkbox"/> Within the most recent year<br>( < 1 year ago) | <input type="checkbox"/> Between 1 and 3 years ago<br>( ≥ 1 year and ≤ 3 years) | <input type="checkbox"/> More than 3 years ago<br>( > 3 years) |
|-------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------|

\*49. Has your facility has ever conducted a water infection control risk assessment (WICRA) to evaluate water sources, modes of transmission, patient susceptibility, patient exposure, and program preparedness? An example WICRA tool can be accessed at <https://www.cdc.gov/hai/pdfs/prevent/water-assessment-tool-508.pdf>

Yes       No

49a. If Yes, when was the most recent assessment conducted? (Check one)

- |                                                                         |                                                                                 |                                                                |
|-------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------|
| <input type="checkbox"/> Within the most recent year<br>( < 1 year ago) | <input type="checkbox"/> Between 1 and 3 years ago<br>( ≥ 1 year and ≤ 3 years) | <input type="checkbox"/> More than 3 years ago<br>( > 3 years) |
|-------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------------------------|

\*50. Does your facility have a water management program (WMP) to prevent the growth and transmission of *Legionella* and other opportunistic waterborne pathogens?

Yes       No

*Continued >>*



## Patient Safety Component—Annual Facility Survey for LTAC

Page 17 of 17

### Facility Water Management Program (WMP) (continued)

50a. If Yes, who is represented on your facility WMP team? (Check all that apply)

- |                                                                           |                                                        |
|---------------------------------------------------------------------------|--------------------------------------------------------|
| <input type="checkbox"/> Hospital Epidemiologist/ Infection Preventionist | <input type="checkbox"/> Compliance/ Safety Officer    |
| <input type="checkbox"/> Hospital Administrator/Leadership                | <input type="checkbox"/> Risk/Quality Management Staff |
| <input type="checkbox"/> Facilities Manager/ Engineer                     | <input type="checkbox"/> Infectious Disease Clinician  |
| <input type="checkbox"/> Maintenance Staff                                | <input type="checkbox"/> Consultant                    |
| <input type="checkbox"/> Equipment/Chemical Acquisition/Supplier          | <input type="checkbox"/> Laboratory Staff              |
| <input type="checkbox"/> Environmental Services                           | <input type="checkbox"/> Other (specify): _____        |

\*51. Does your facility regularly monitor the following parameters in the building water system(s)? (Check all that apply)

- |                                                                                                                                                                                                |                              |                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-----------------------------|
| Disinfectant (such as residual chlorine):                                                                                                                                                      | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| If Yes, does your facility have a plan for corrective actions when disinfectant(s) are not within acceptable limits as determined by the water management program?                             | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Temperature:                                                                                                                                                                                   | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| If Yes, does your facility have a plan for corrective actions when temperatures are not within acceptable limits as determined by the water management program?                                | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Heterotrophic plate counts:                                                                                                                                                                    | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| If Yes, does your facility have a plan for corrective actions when heterotrophic plate counts are not within acceptable limits as determined by the water management program?                  | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| Specific environmental testing for <i>Legionella</i> :                                                                                                                                         | <input type="checkbox"/> Yes | <input type="checkbox"/> No |
| If Yes, does your facility have a plan for corrective actions when environmental testing for <i>Legionella</i> are not within acceptable limits as determined by the water management program? | <input type="checkbox"/> Yes | <input type="checkbox"/> No |